OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer

What this Trial Is About

Researchers are evaluating whether ovarian cancer patients who are homologous recombination deficient negative (HRDneg) benefit when additional detailed tumor information is used by a specialized molecular tumor board to guide treatment recommendations. This study focuses on patients with poor outcomes under standard chemotherapy and aims to find personalized treatment options based on individual tumor profiles. The trial compares usual care against care guided by these molecular tumor board recommendations to see if this approach better supports treatment decisions. The study involves two groups: one receiving standard chemotherapy consisting of two cycles of carboplatin and paclitaxel either every three weeks or weekly, and the other receiving personalized treatment recommendations developed by the molecular tumor board using tumor profiling data from the participant's specimens. The tumor profiling combines multiple precision-cancer analysis methods to rank effective drugs and experimental treatments tailored to each patient. The study includes an initial diagnostic phase to determine HRD status and perform tumor profiling before randomization into treatment groups. Participants will be assessed on how often the tumor board suggests different treatment options, how well oncologists feel supported by the tumor board recommendations, and differences in treatment choices between patients and doctors. Additional evaluations include patient-reported benefits and clinical outcomes over approximately 10 weeks after treatment starts. The research will take place over about three years including recruitment, treatment, and analysis, with ongoing monitoring and data collection throughout the study period.

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy